Drug Profile
Miconazole - Tibotec
Alternative Names: TibozoleLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Tibotec Pharmaceuticals
- Developer Janssen Therapeutics; RHEI Pharmaceuticals
- Class Antifungals; Imidazoles; Small molecules
- Mechanism of Action Cell membrane modulators; Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Oropharyngeal candidiasis
Most Recent Events
- 09 Apr 2015 Miconazole is approved and is in phase-III development for Oropharyngeal candidiasis in Ukraine, Africa and China, respectively
- 27 Aug 2012 Phase III development is ongoing in China
- 09 Dec 2008 Phase-III clinical trials in Oropharyngeal candidiasis in China (Buccal)